426 related articles for article (PubMed ID: 24209829)
1. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
[TBL] [Abstract][Full Text] [Related]
2. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.
Payne H; Mkhize N; Otwombe K; Lewis J; Panchia R; Callard R; Morris L; Babiker A; Violari A; Cotton MF; Klein NJ; Gibb DM
Lancet Infect Dis; 2015 Jul; 15(7):803-9. PubMed ID: 26043884
[TBL] [Abstract][Full Text] [Related]
3. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
4. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy.
Laughton B; Cornell M; Kidd M; Springer PE; Dobbels EFM; Rensburg AJV; Otwombe K; Babiker A; Gibb DM; Violari A; Kruger M; Cotton MF
J Int AIDS Soc; 2018 May; 21(5):e25106. PubMed ID: 29722482
[TBL] [Abstract][Full Text] [Related]
5. Early antiretroviral therapy and mortality among HIV-infected infants.
Violari A; Cotton MF; Gibb DM; Babiker AG; Steyn J; Madhi SA; Jean-Philippe P; McIntyre JA;
N Engl J Med; 2008 Nov; 359(21):2233-44. PubMed ID: 19020325
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
8. Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation.
van Wyhe KS; Laughton B; Cotton MF; Meintjes EM; van der Kouwe AJ; Boivin MJ; Kidd M; Thomas KG
J Int AIDS Soc; 2021 Jul; 24(7):e25734. PubMed ID: 34259393
[TBL] [Abstract][Full Text] [Related]
9. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
[TBL] [Abstract][Full Text] [Related]
12. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
[TBL] [Abstract][Full Text] [Related]
13. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
14. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
[TBL] [Abstract][Full Text] [Related]
15. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
16. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
BREATHER (PENTA 16) Trial Group
Lancet HIV; 2016 Sep; 3(9):e421-e430. PubMed ID: 27562743
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
18. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
19. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
20. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
